Equity · Healthcare
DNA
NYSEGinkgo Bioworks Holdings (DNA)
The line runs 7 USD on 24 August through 10.66 USD on 25 September, on a scale from 6 to 12. Days the market did not trade hold the previous close, flat.
- Market cap
- 590.9M USD
- Revenue, year to Dec 2025
- 170.2M USD
- EPS, diluted, year to Dec 2025
- −5.64 USD
- 52-week range
- 5 USD – 16.15 USD
- Avg volume
- 77.1K
as of Sep 25, 2026
Have Ginkgo Bioworks Holdings (DNA) insiders bought or sold shares recently?
In the 90 days to 31 Oct 2026, Ginkgo Bioworks Holdings insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase.
Form 4, 90 days to 31 Oct 2026, newest reported trade 19 Oct 2026
Buys 0Sells 7Net sold $1.38MOther filings 5
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Oct 2026 | Canton Barry10% Owner | Sell | 41,172 | 418K USD |
| 19 Oct 2026 | Coen Steven P.See remarks | Sell | 766 | 8K USD |
| 19 Oct 2026 | Kelly Jason RSee remarks | Sell | 45,682 | 463K USD |
| 19 Oct 2026 | Shetty Reshma P.See remarks | Sell | 41,172 | 418K USD |
| 05 Oct 2026 | Coen Steven P.See remarks | Sell | 2,403 | 36K USD |
| 15 Sep 2026 | HENRY CHRISTIAN ODirector | Sell | 5,000 | 35K USD |
| 24 Aug 2026 | Coen Steven P.See remarks | Sell | 330 | 2K USD |
| Sold | 7 open-market sales | 136,525 | $1.38M |
5 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Oct 2026 | Canton Barry10% Owner | Option exercise | 76,462 | |
| 16 Oct 2026 | Coen Steven P.See remarks | Option exercise | 1,486 | |
| 16 Oct 2026 | Kelly Jason RSee remarks | Option exercise | 81,484 | |
| 16 Oct 2026 | Shetty Reshma P.See remarks | Option exercise | 76,462 | |
| 21 Aug 2026 | Coen Steven P.See remarks | Option exercise | 743 |
Which funds hold Ginkgo Bioworks Holdings (DNA)?
10 of the 45 institutional funds we track reported a Ginkgo Bioworks Holdings position for the quarter ended 30 Jun 2026 — a combined 61.0M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Viking Global Investors | Held (±25%) | 3,577,128 | 35.4M USD | |
| Millennium Management | Added | 638,676 | 6.3M USD | +30.9% |
| AQR Capital Management | Added | 621,625 | 6.2M USD | +110.9% |
| Renaissance Technologies | Added | 539,856 | 5.3M USD | +437.4% |
| Tudor Investment Corp | Trimmed | 335,710 | 3.3M USD | −27.8% |
| D. E. Shaw & Co. | Added | 151,356 | 1.5M USD | +457.1% |
| Citadel Advisors | New position | 130,935 | 1.3M USD | |
| Marshall Wace | New position | 77,937 | 772K USD | |
| Two Sigma Investments | Held (±25%) | 60,454 | 599K USD | −5.0% |
| Man Group | Trimmed | 24,208 | 240K USD | −77.8% |
Ginkgo Bioworks Holdings (DNA) US federal contracts
US federal agencies committed 28.8M USD in contracts to Ginkgo Bioworks Holdings (DNA) in fiscal 2026, the year to 30 Sep 2026, against 4.0M USD the year before.
USAspending.gov
Fiscal 2026 28.8M USDFiscal 2025 4.0M USDFiscal 2024 67.2M USD
| Signed | Agency | Contract | Committed |
|---|---|---|---|
| 03 May 2026 | Centers for Disease Control and PreventionDepartment of Health and Human Services | METAGENOMIC NEXT-GENERATION SEQUENCING (MNGS)REFERENCE LABORATORY TESTING · 75D30126F00004 | 3.2M USD |
| 17 Jan 2025 | Centers for Disease Control and PreventionDepartment of Health and Human Services | TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAMSUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT · 75D30125C20439 | 78.0M USD |
| 15 Jan 2025 | Centers for Disease Control and PreventionDepartment of Health and Human Services | TEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30125F00003 | 450K USD |
| 27 Sep 2024 | Centers for Disease Control and PreventionDepartment of Health and Human Services | TEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30124F00002 | 775K USD |
| 06 Sep 2024 | Centers for Disease Control and PreventionDepartment of Health and Human Services | TEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQREFERENCE LABORATORY TESTING · 75D30124F00001 | 3.8M USD |
| 26 Aug 2024 | Centers for Disease Control and PreventionDepartment of Health and Human Services | TRAVELER-BASED GENOMIC SURVEILLANCESUPPORT- PROFESSIONAL: PROGRAM MANAGEMENT/SUPPORT · 75D30124C19895 | 1.2M USD |
| 29 Jan 2024 | Defense Advanced Research Projects AgencyDepartment of Defense | DARPA ICE CONTROL FOR COLD ENVIRONMENTS (ICE)NATIONAL DEFENSE R&D SERVICES; DEPARTMENT OF DEFENSE - MILITARY; APPLIED RESEARCH · HR001124C0378 | 5.2M USD |
| 02 May 2023 | Department of the NavyDepartment of Defense | DNA RECORDING INTRINSIC CELLULAR BIOINTELLIGENCE (DRINC BIO)GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH · N6600123C4509 | 1.8M USD |
| 15 Dec 2022 | Department of the ArmyDepartment of Defense | DARPA CONTRACT AWARD (BASE) "SUPERB: SYNBIO + UNIVERSAL PURIFICATION OF EXTRACT-DERIVED, RIGHT-ON-TIME BIOLOGICS"GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH · W911NF23C0002 | 4.8M USD |
| 16 Aug 2022 | Centers for Disease Control and PreventionDepartment of Health and Human Services | AIRPORT GENOMIC TESTINGSPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL · 75D30122C14933 | 62.6M USD |
Contracts of US$100,000 or more signed since April 2022; the amount is what the government has committed so far, which grows when options are exercised. Defense Department contracts are published about 90 days after signing, so the latest year is still filling in.
What has been filed or recorded for Ginkgo Bioworks Holdings (DNA)?
The filings we hold for Ginkgo Bioworks Holdings, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,934 shares | 58K USD notional · 0.009% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 18,216 shares | 209K USD notional · 0.033% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 213 shares | 3K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 1,100 shares | 13K USD notional · 0.002% of shares out |
| 25 Sep 2026 | Fails to deliver | Shares failed to deliver | 258 shares | 3K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | Revenue $20M | |
| 30 Jun 2026 | Financials | Total assets | 990.0M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 420.3M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | Revenue $19M | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −5.64 USD | Revenue $170M |
| 31 Dec 2025 | Financials | Revenue | 170.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −312.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −5.64 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.45 USD | Revenue $39M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.10 USD | Revenue $39M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.68 USD | Revenue $38M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −10.54 USD | Revenue $227M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.08 USD | Revenue $89M |
Ginkgo Bioworks Holdings (DNA): frequently asked questions
What did Ginkgo Bioworks Holdings shares close at?
Ginkgo Bioworks Holdings closed at 10.66 USD on 25 Sep 2026, up 6.55% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Ginkgo Bioworks Holdings’ market cap?
Ginkgo Bioworks Holdings is worth 590.9M USD by market value as of 25 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Ginkgo Bioworks Holdings’ revenue?
Ginkgo Bioworks Holdings reported revenue of 170.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Ginkgo Bioworks Holdings insiders bought or sold shares recently?
In the 90 days to 31 Oct 2026, Ginkgo Bioworks Holdings insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Ginkgo Bioworks Holdings?
10 of the 45 funds we track reported a Ginkgo Bioworks Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, Millennium Management and AQR Capital Management. See Funds
When did Ginkgo Bioworks Holdings last report earnings?
Ginkgo Bioworks Holdings last reported earnings on 30 Jun 2026 for Q2 2026; no next date is announced in SEC filings yet. See Filings
Does Ginkgo Bioworks Holdings have government contracts?
Yes. US federal agencies committed 28.8M USD in contracts to it in fiscal 2026, the year to 30 Sep 2026 (USAspending.gov). See Contracts
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- USAspendingUSAspending.gov (U.S. Department of the Treasury), federal prime contract awards
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings